Quillichew Er is an oral medication owned by Nextwave Pharms. The active ingredient in Quillichew Er is methylphenidate hydrochloride. It was first approved for use on the 4th of December, 2015.
The generic version of Quillichew Er might be available post the 14th of August, 2033, when the last patent expires.
Quillichew Er is used to provide a therapeutically effective amount of racemic methylphenidate by oral administration. It is administered as an extended-release chewable tablet and is primarily used for treating ADHD.
Quillichew Er holds a total of 10 patents, with none having expired so far. The expiry of the last patent for Quillichew Er is slated for the 14th August, 2033, thus marking the potential release date for Quillichew Er generic. Below are the details of the patent: